VEGF inhibitors for the treatment of malignant pleural effusion

Details for Australian Patent Application No. 2005265071 (hide)

Owner Memorial Sloan-Kettering Cancer Center Regeneron Pharmaceuticals, Inc.

Inventors Azzoli, Christopher, G.; Dupont, Jakob; Cedarbaum, Jesse, M.; Kris, Mark, G.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2005265071

PCT Pub. Number WO2006/009809

Priority 60/580,893 18.06.04 US

Filing date 17 June 2005

Wipo publication date 26 January 2006

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

A61P 35/00 (2006.01) Antineoplastic agents

C07K 14/71 (2006.01) Peptides having more than 20 amino acids

Event Publications

21 December 2006 PCT application entered the National Phase

  PCT publication WO2006/009809 Priority application(s): WO2006/009809

23 April 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005265078-ATM machine and methods with currency conversion capabilities

2005265068-Composite closure with barrier end panel